| Table 3: | ||
|
Anastrozole
vs. Tamoxifen: Significant Differences In Rates of Adverse Effects |
||
| Anastrozole | Tamoxifen | |
| Endometrial cancer | 0.1% | 0.7% |
| Fractures | 7.1% | 4.4% |
| Hot flashes | 35.0% | 40.3% |
| Ischemic cerebrovascular events | 1.1% | 2.3% |
| Vaginal bleeding | 4.8% | 8.7% |
| Vaginal discharge | 3.0% | 12.2% |
| Venous thromboembolic events | 2.2% | 3.9% |
|
Copyright
2003 The Cleveland Clinic Foundation
|
Return to Breast Cancer Risk Assessment and Prevention Chapter